PCI announces expansion of its Tredegar facility

Pharmaceutical outsourcing services provider, PCI Pharma Services, has announced the expansion of analytical laboratories at its centre of excellence for contained manufacturing in Tredegar, UK.

This latest investment in the Tredegar facility will increase the company’s analyst headcount by approximately 60% and will also increase its high-performance liquid chromatography (HPLC) capacity by more than 20%. Additionally, the company will triple its capacity for sample receipt.

“Expansion of our laboratory services is an important program for the Tredegar site,” revealed PCI senior vice president, International, Richard Yarwood. “Speed to market is of critical importance to our clients. We pride ourselves on continually improving our service for both existing and potential new clients and our analytical service is integral from the early stages of analytical development through to commercial launch and the associated annual stability testing.”

Since the launch of the companies contained manufacturing facility, the company has seen significant growth in its global customer base. This latest investment will ensure the company can serve existing and potential new clients in addition to offering a project initiation in terms of analytical transfer within 4-6 weeks.

“Among our many key strengths is our ability to on-board projects faster than our competitors,” continued Yarwood. “This additional footprint will ensure we are able to continue to offer this speed of project initiation addressing customer need.”